US study suggests GLP-1 RA drugs are associated with small increase in ischemic optic neuropathy

Article excerpt

A target trial emulation found that people with type 2 diabetes who started glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy had a slightly higher risk of ischemic optic neuropathy (ION), a rare condition involving reduced blood flow to the optic nerve that can cause sudden vision loss, compared with those initiating sodium, glucose cotransporter-2 inhibitors (SGLT2is) or dipeptidyl peptidase-4 inhibitors (DPP4is); however, absolute risk was very low.